Press "Enter" to skip to content

FDA issues warning letter to Alkermes over opioid addiction treatment ad

Users of Vivitrol as a treatment for opioid dependence should be made aware of the vulnerability to potentially fatal overdose at the end of a dosing interval, after missing a dose, or after discontinuing the treatment, the agency said in the letter dated Dec. 2.

Original source: https://health.economictimes.indiatimes.com/news/pharma/fda-issues-warning-letter-to-alkermes-over-opioid-addiction-treatment-ad/72493597?utm_source=RSS&utm_medium=ETRSS

Also Read:   Bayer says it is looking into established drugs strategy